Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Comment by forhandlarenon Jan 30, 2024 5:17pm
112 Views
Post# 35853678

RE:RE:RE:RE:RE:RE:RE:ANTICIPATED PRODUCT LINE PRESS RELEASE

RE:RE:RE:RE:RE:RE:RE:ANTICIPATED PRODUCT LINE PRESS RELEASEI certainly agree about the communication after the Allergan deal. Unfortunately, the communication was typical for Howard which took some time to grasp.

Howard like to present a carrot that he intends to deliver, but usually without any commitment time-wize. The receiver of the communication make a perfectly valid interpretation that Howard is about to deliver short term, but he does not intend to do so. There's wiggle-room for long term. This suits him very well.

The new CEO is a great example. I think we all thought reqruitment had started, but long after he made a statement that the company must be profitable to afford. Did he lie about a new CEO? No..! It is a matter of timing. I would love a new CEO, but realize that it won't happen before 2025.

I think this kind of communication only leads to mistrust and here we are!

However, now after more than 18 months they start to deliver on transparency. More can be achieved for sure. It's much better than before so I'm willing to give them anotjer chance instead of bitterness.

Why don't you ask them exactly who support them in strategic business nowadays? Please share. I think it's Atheln, if not I'm happy anyway because I think they finally are on track.

The current plan requires fast track of events to occur so we can all deem pretty fast if the launch dates are realistic or not.
<< Previous
Bullboard Posts
Next >>